Literature DB >> 23047830

Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.

Athol U Wells, Juergen Behr, Ulrich Costabel, Vincent Cottin, Venerino Poletti, Luca Richeldi.   

Abstract

Mesh：

Year:  2012        PMID： 23047830     DOI： 10.1136/thoraxjnl-2012-202580

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  19 in total

1.  Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Kevin K Brown; Fernando J Martinez; Ganesh Raghu; Rhonda S Roberts; Kevin J Anstrom
Journal:  Chest       Date:  2014-11       Impact factor: 9.410

2.  Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

Authors:  Matthew R Lammi; Robert P Baughman; Surinder S Birring; Anne-Marie Russell; Jay H Ryu; Marybeth Scholand; Oliver Distler; Daphne LeSage; Catherine Sarver; Katerina Antoniou; Kristin B Highland; Otylia Kowal-Bielecka; Joseph A Lasky; Athol U Wells; Lesley Ann Saketkoo
Journal:  Curr Respir Med Rev       Date:  2015

3.  Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.

Authors:  Andrew M Wilson; Allan B Clark; Tony Cahn; Edwin R Chilvers; William Fraser; Matthew Hammond; David M Livermore; Toby M Maher; Helen Parfrey; Ann Marie Swart; Susan Stirling; David R Thickett; Moira Whyte
Journal:  JAMA       Date:  2020-12-08       Impact factor: 56.272

Review 4.  Interstitial lung disease points to consider for clinical trials in systemic sclerosis.

Authors:  Dinesh Khanna; James Seibold; Jonathan Goldin; Donald P Tashkin; Daniel E Furst; Athol Wells
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

5.  The need for patient-centred clinical research in idiopathic pulmonary fibrosis.

Authors:  Anne-Marie Russell; Mirjam A G Sprangers; Steven Wibberley; Noel Snell; Daniel M Rose; Jeff J Swigris
Journal:  BMC Med       Date:  2015-09-24       Impact factor: 8.775

Review 6.  Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis.

Authors:  Yoshito Takeda; Kazuyuki Tsujino; Takashi Kijima; Atsushi Kumanogoh
Journal:  Patient Prefer Adherence       Date:  2014-03-21       Impact factor: 2.711

Review 7.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

Review 8.  Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.

Authors:  Hannah V Woodcock; Philip L Molyneaux; Toby M Maher
Journal:  Drug Des Devel Ther       Date:  2013-06-19       Impact factor: 4.162

Review 9.  The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis.

Authors:  Vincent Cottin
Journal:  Respir Res       Date:  2013-04-16

10.  Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis.

Authors:  Akihiko Sokai; Tomohiro Handa; Kiminobu Tanizawa; Toru Oga; Kazuko Uno; Tatsuaki Tsuruyama; Takeshi Kubo; Kohei Ikezoe; Yoshinari Nakatsuka; Kazuya Tanimura; Shigeo Muro; Toyohiro Hirai; Sonoko Nagai; Kazuo Chin; Michiaki Mishima
Journal:  Respir Res       Date:  2015-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.